List view / Grid view

R&D

 

Biomarkers for cancer treatment

22 October 2013 | By Amancio Carnero, Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas

There is an urgent need to predict which treatment will report the most benefit to a patient with cancer. To that end, scientists are exploring any possible biomolecule in the organism that can mark each individual for its adequate treatment. If achieved, it will open a personalised medicine era.

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

7 October 2013 | By

Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…

Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes

24 September 2013 | By Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D).  These data were presented…

Proteases: How naturally occurring inhibitors can facilitate small molecule drug discovery for cysteine proteases

20 August 2013 | By Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH

Cysteine proteases are expressed ubiquitously in the animal and plant kingdom and are thought to play key roles in maintaining homeostasis. The aberrant function of cysteine proteases in humans are known to lead to a variety of epidermal disease states such as inflammatory skin disease1. In marked contrast, the serine…

Raman spectroscopy: an enabling tool for accelerating pharmaceutical discovery to development

20 August 2013 | By Chanda R. Yonzon, Atul Karande, Sai P. Chamarthy and Brent A. Donovan (Merck & Co. Inc)

Raman spectroscopy has emerged as the preeminent analytical tool for a number of applications within drug discovery and development. Advances in the instrumentation, sensor fabrication and data analysis have enabled the wider acceptance of Raman spectroscopy1,2. In discovery, Raman spectroscopy is used to elucidate structural activity relationships3 and to optimise…

GPCRs: Cell based label-free assays in GPCR drug discovery

20 August 2013 | By Niklas Larsson, Linda Sundström, Erik Ryberg and Lovisa Frostne (AstraZeneca)

G protein-coupled receptors are one of the major classes of therapeutic targets for a broad range of diseases. The most commonly used assays in GPCR drug discovery measure production of second messengers such as cAMP or IP3 that are the result of activation of individual signalling pathways. Such specific assays…

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

15 August 2013 | By OgilvyHealthPR London

Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…

Send this to a friend